Biomark Diagnostics Inc. (FRA:20B)
Germany · Delayed Price · Currency is EUR 0.2860
0.00 (0.00%)
Last updated: Aug 24, 2026, 8:04 AM CET
Biomark Diagnostics Balance Sheet
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 0.62 | 2.48 | 0.16 | 0.07 | 0.38 |
Short-Term Investments | 0.39 | - | - | - | - |
Cash & Short-Term Investments | 1.01 | 2.48 | 0.16 | 0.07 | 0.38 |
Cash Growth | -59.27% | 1483.27% | 117.59% | -81.18% | -56.39% |
Accounts Receivable | 0.05 | 0.16 | 0.04 | 0.03 | 0.08 |
Receivables | 0.05 | 0.16 | 0.04 | 0.03 | 0.08 |
Prepaid Expenses | 0.02 | - | - | 0.02 | 0.03 |
Total Current Assets | 1.08 | 2.64 | 0.2 | 0.13 | 0.5 |
Property, Plant & Equipment | 0.72 | 0.45 | 0.85 | 0.59 | 0.97 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
Other Long-Term Assets | 0.05 | 0.03 | 0.03 | 0.01 | - |
Total Assets | 1.86 | 3.13 | 1.09 | 0.73 | 1.47 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 0.1 | 0.27 | 0.14 | 0.22 | 0.13 |
Short-Term Debt | 0.7 | 0.66 | 0.74 | 1.06 | 1.06 |
Current Portion of Long-Term Debt | - | - | - | 0.1 | - |
Current Portion of Leases | 0.29 | 0.29 | 0.35 | 0.28 | 0.3 |
Other Current Liabilities | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Total Current Liabilities | 1.1 | 1.23 | 1.24 | 1.66 | 1.5 |
Long-Term Debt | - | - | - | - | 0.1 |
Long-Term Leases | 0.43 | 0.16 | 0.45 | 0.22 | 0.51 |
Total Liabilities | 1.53 | 1.39 | 1.7 | 1.88 | 2.11 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 13.78 | 13.78 | 10.14 | 8.24 | 7.12 |
Additional Paid-In Capital | 3.78 | 3.73 | 2.35 | 2.23 | 1.7 |
Retained Earnings | -17.25 | -15.77 | -13.45 | -11.98 | -10.12 |
Comprehensive Income & Other | 0.02 | - | 0.35 | 0.36 | 0.66 |
Shareholders' Equity | 0.33 | 1.74 | -0.61 | -1.15 | -0.64 |
Total Liabilities & Equity | 1.86 | 3.13 | 1.09 | 0.73 | 1.47 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 1.42 | 1.12 | 1.55 | 1.65 | 1.97 |
Net Cash (Debt) | -0.41 | 1.36 | -1.39 | -1.58 | -1.58 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -0.00 | 0.01 | -0.02 | -0.02 | -0.02 |
Filing Date Shares Outstanding | 106.48 | 105.09 | 90.89 | 83.29 | 77.97 |
Total Common Shares Outstanding | 105.09 | 105.09 | 90.89 | 83.29 | 77.97 |
Working Capital | -0.01 | 1.41 | -1.04 | -1.54 | -1 |
Book Value Per Share | 0.00 | 0.02 | -0.01 | -0.01 | -0.01 |
Tangible Book Value | 0.33 | 1.74 | -0.61 | -1.15 | -0.64 |
Tangible Book Value Per Share | 0.00 | 0.02 | -0.01 | -0.01 | -0.01 |
Machinery | 0.08 | 0.07 | 0.07 | 0.06 | 0.06 |